title: Thyrotropin-secreting pituitary carcinoma.
abstract: Pituitary tumors rarely metastasize outside the central nervous system. Of the more than 100 reported TSH-secreting adenomas, we now describe the first carcinoma. A 40-yr-old woman had transsphenoidal surgery for a large TSH-secreting pituitary adenoma in 1984. She had increased thyroid hormone levels with a TSH that varied from 16-31 microU/mL, and an unusually high alpha-subunit that ranged from 125-150 ng/mL. Because of residual tumor, she had a left craniotomy in 1985 followed by radiation. Despite these therapies, she had a residual tumor that remained stable until January 1989 when her tumor nearly doubled in size. She received radiation therapy and octreotide with marked diminution of the tumor and clinical improvement. In August 1989, she presented with leg weakness, and magnetic resonance imaging revealed a large sacral mass. A biopsy confirmed that the sacral mass was a metastasis from the pituitary tumor. Due to additional metastases in the lung, she received 5-fluorouracil, cytoxan, and adriamycin, with marked decrease in her lesions. Further substantiation of the metastatic pituitary tumor was made when the patient returned in December 1989 with a pleural effusion containing pituitary tumor cells. Of all the reported cases of TSH-secreting adenomas, this case had the highest alpha-subunit portending future metastases. Furthermore, the apparent response to octreotide and response to chemotherapy are encouraging and suggest that new therapies should be explored. Finally, since TSH-secreting adenomas tend to be more invasive than other pituitary tumors, this case underscores the need for early diagnosis and aggressive treatment of these tumors.
authors.affiliation: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892.
authors.forename: A J
authors.initials: AJ
authors.lastname: Mixson
authors.forename: T C
authors.initials: TC
authors.lastname: Friedman
authors.forename: D A
authors.initials: DA
authors.lastname: Katz
authors.forename: I M
authors.initials: IM
authors.lastname: Feuerstein
authors.forename: J K
authors.initials: JK
authors.lastname: Taubenberger
authors.forename: J M
authors.initials: JM
authors.lastname: Colandrea
authors.forename: J L
authors.initials: JL
authors.lastname: Doppman
authors.forename: E H
authors.initials: EH
authors.lastname: Oldfield
authors.forename: B D
authors.initials: BD
authors.lastname: Weintraub
mesh_terms: D000328:Adult; D001859:Bone Neoplasms / Q000556:secondary; D001932:Brain Neoplasms / Q000556:secondary; D002277:Carcinoma / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008279:Magnetic Resonance Imaging; D009362:Neoplasm Metastasis; D015282:Octreotide / Q000627:therapeutic use; D010911:Pituitary Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D016066:Pleural Effusion, Malignant / Q000473:pathology; D013972:Thyrotropin / Q000378:metabolism*
chemical_list: D013972:Thyrotropin; D015282:Octreotide